Elucidating Compound Mechanism of Action and Polypharmacology with a Large-scale Perturbational Profile Compendium
Hu, L. Z.; Douglass, E.; Turunen, M.; Pampou, S.; Grunn, A.; Realubit, R.; Antolin, A. A.; Wang, A. L. E.; Li, H.; Subramaniam, P.; Karan, C.; Alvarez, M.; Califano, A.
Show abstract
Drug Mechanism of Action (MoA) is generally represented as a small repertoire of tissue-independent, high-affinity binding targets. Yet, drug activity and polypharmacology are associated with a broad range of off-target and tissue-specific effector proteins. To address this challenge, we have generated a compendium of drug perturbation profiles for >700 oncology drugs in cell lines representing high-fidelity models of 23 aggressive tumor subtypes and developed an integrative computational framework for the proteome-wide assessment of drug-mediated, tissue-specific differential protein activity. This allows systematic, mechanism-based elucidation of tissue context-specific compound MoA and polypharmacology, including discovery and experimental validation of post-translationally-mediated inhibition of undruggable oncoproteins--such as MYC, CTNNB1, CENPF and UHRF1--as well as previously unknown inhibitors of MAPK, PI3K, and folate pathways, among others, as further suggested by protein structure analysis. This framework can help characterize the MoA of discovery compound libraries, thus supporting more systematic and quantitative approaches to precision oncology.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma. 97%
- Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones 96%
- Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations 96%
Similar papers in this journal
- Predicting the Tumor Microenvironment Composition and Immunotherapy Response in Non-Small Cell Lung Cancer from Digital Histopathology Images 94%
- Multi-omics analysis of serial samples from metastatic TNBC patients on PARP inhibitor monotherapy provide insight into rational PARP inhibitor therapy combinations 92%
- Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations 92%
Similar papers in this journal
Similar papers in this journal
- LIGHTHOUSE illuminates therapeutics for a variety of diseases including COVID-19 96%
- Inference of drug off-target effects on cellular signaling using Interactome-Based Deep Learning 96%
- NDC80 status pinpoints mitotic kinase inhibitors as emerging therapeutic options in clear cell renal cell carcinoma 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.